<DOC>
	<DOCNO>NCT02683317</DOCNO>
	<brief_summary>The purpose study evaluate whether docosahexaenoic acid give enteral feed prevent retinopathy prematurity and/or diminish severity preterm infant .</brief_summary>
	<brief_title>Enteral Administration Docosahexaenoic Acid Prevent Retinopathy Prematurity</brief_title>
	<detailed_description>Preterm neonates start receive enteral feed receive intervention docosahexaenoic acid ( DHA ) since first day throughout 14 day , one dose per day . The opthalmic evaluation do 4-5 week birth follow 42-45 correct gestational age .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<criteria>Birth weight &lt; 1500 g Plan fee enteral way short term Written inform consent , sign parent . Congenital malformation avoid enteral feeding immunosuppressor disease Need major surgery Persistent bleed level Mother take n3 supplement plan breastfed Parents decline authorization participate study Early discharge hospital outside metropolitan area</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Weeks</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>DHA</keyword>
	<keyword>Retinopathy Prematurity</keyword>
</DOC>